Barzolvolimab Atopic Dermatitis Trial Fails: Celldex Drops Eczema to Focus on Hives
Celldex is ending barzolvolimab development in atopic dermatitis after a 131-patient Phase 2 missed its itch endpoint at both doses. The data, the biology behind the miss and what remains in the pipeline.
